2009-2015年美国丙型肝炎抗病毒药物支出

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2017-01-01 DOI:10.1002/phar.1865

K. Suda, Drew J. Halbur, R. Hunkler, Linda M. Matusiak, G. Schumock

{"title":"2009-2015年美国丙型肝炎抗病毒药物支出","authors":"K. Suda, Drew J. Halbur, R. Hunkler, Linda M. Matusiak, G. Schumock","doi":"10.1002/phar.1865","DOIUrl":null,"url":null,"abstract":"New hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known, however, about the impact of the new HCV antivirals on expenditures in the overall U.S. health care system or by health care sector. Thus the objective of this study was to describe HCV antiviral expenditures by agent, year, and health care sector.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Spending on Hepatitis C Antivirals in the United States, 2009–2015\",\"authors\":\"K. Suda, Drew J. Halbur, R. Hunkler, Linda M. Matusiak, G. Schumock\",\"doi\":\"10.1002/phar.1865\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known, however, about the impact of the new HCV antivirals on expenditures in the overall U.S. health care system or by health care sector. Thus the objective of this study was to describe HCV antiviral expenditures by agent, year, and health care sector.\",\"PeriodicalId\":19812,\"journal\":{\"name\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/phar.1865\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/phar.1865","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

摘要

新的丙型肝炎病毒(HCV)抗病毒药物已被证明非常有效，副作用最小，但它们价格昂贵。然而，关于新的HCV抗病毒药物对整个美国卫生保健系统或卫生保健部门支出的影响知之甚少。因此，本研究的目的是描述按药物、年份和卫生保健部门划分的HCV抗病毒费用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Spending on Hepatitis C Antivirals in the United States, 2009–2015

New hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known, however, about the impact of the new HCV antivirals on expenditures in the overall U.S. health care system or by health care sector. Thus the objective of this study was to describe HCV antiviral expenditures by agent, year, and health care sector.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

自引率

0.00%

发文量